This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Teleflex (TFX) New Survey Highlights BPH Impact Life Quality
by Zacks Equity Research
Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).
Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
by Zacks Equity Research
Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.
Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.
Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).
Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes
by Zacks Equity Research
Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval
by Zacks Equity Research
Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.
Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod
by Zacks Equity Research
Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Teleflex (TFX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 4.04% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra (SIEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sientra (SIEN) delivered earnings and revenue surprises of -137.50% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.
Teleflex (TFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Teleflex (TFX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Teleflex (TFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex
by Zacks Equity Research
Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex are part of the Zacks top Analyst Blog.
Top Analyst Reports for Comcast, Aon & Trane Technologies
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Aon plc (AON) and Trane Technologies plc (TT).